Form 8-K - Current report:
SEC Accession No. 0001731122-25-001591
Filing Date
2025-11-25
Accepted
2025-11-25 07:30:48
Documents
13
Period of Report
2025-11-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e7068_8k.htm   iXBRL 8-K 26386
2 EXHIBIT 99.1 e7068_ex99-1.htm EX-99.1 108330
  Complete submission text file 0001731122-25-001591.txt   311644

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avxl-20251125.xsd EX-101.SCH 2990
4 XBRL LABEL FILE avxl-20251125_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE avxl-20251125_pre.xml EX-101.PRE 22342
15 EXTRACTED XBRL INSTANCE DOCUMENT e7068_8k_htm.xml XML 3687
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 251515047
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)